Halozyme Therapeutics | HALO - Loan Capital


Halozyme Therapeutics reported $2.14B in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Baxter International USD 9.47B 726M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.12B 957.23M Dec/2025
DBV Technologies USD 0 0 Mar/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
MannKind USD 548.44M 244.79M Dec/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Pfizer USD 57.41B 93M Sep/2025
Rigel Pharmaceuticals USD 0 0 Sep/2024
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024